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Background: Previous studies have reported the prognostic impact of primary tumor sidedness in metastatic colorectal cancer
(mCRC) and its influence on cetuximab efficacy. The present retrospective analysis of two panitumumab trials investigated a
possible association between tumor sidedness and treatment efficacy in first-line mCRC patients with RAS wild-type (WT) pri-
mary tumors.
Materials and methods: Data from two randomized first-line panitumumab trials were analyzed for treatment outcomes by
primary tumor sidedness for RASWT patients. PRIME (phase 3; NCT00364013) compared panitumumab plus FOLFOX versus
FOLFOX alone; PEAK (phase 2; NCT00819780) compared panitumumab plus FOLFOX versus bevacizumab plus FOLFOX. Primary
tumors located in the cecum to transverse colon were coded as right-sided, while tumors located from the splenic flexure to
rectum were considered left-sided.
Results: Tumor sidedness ascertainment (RAS WT population) was 83% (n¼ 559/675); 78% of patients (n¼ 435) had left-sided
and 22% (n¼ 124) had right-sided tumors. Patients with right-sided tumors did worse for all efficacy parameters compared with
patients with left-sided disease in the RAS WT population and also in the RAS/BRAF WT subgroup. In patients with left-sided
tumors, panitumumab provided better outcomes than the comparator treatment, including on median overall survival (PRIME:
30.3 versus 23.6months, adjusted hazard ratio¼ 0.73, P¼ 0.0112; PEAK: 43.4 versus 32.0months, adjusted hazard ratio¼ 0.77,
P¼ 0.3125).
Conclusion: The results of these retrospective analyses confirm that in RAS WT patients, right-sided primary tumors are associ-
ated with worse prognosis than left-sided tumors, regardless of first-line treatment received. RASWT patients with left-sided
tumors derive greater benefit from panitumumab-containing treatment than chemotherapy alone or combined with bevacizu-
mab, including an overall survival advantage (treatment difference: PRIME 6.7months; PEAK 11.4months). No final conclusions
regarding optimal treatment could be drawn for RASWT patients with right-sided mCRC due to the relatively low number of
paxtients. Further research in this field is warranted.
Trial registration (Clinicaltrials.gov): PRIME (NCT00364013), PEAK (NCT00819780).
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Introduction
Colorectal cancer (CRC) is the third most commonly diagnosed
cancer worldwide with over 1.3 million new diagnoses and
694 000 deaths in 2012 [1]. During the last decade, with improve-
ments in treatment strategies such as the implementation of
chemotherapy and new biological agents [2], median survival has
increased from 12 to up to 30 months for some patients with
metastatic CRC (mCRC) [3, 4].
Recently, RAS mutations (KRAS and NRAS exons 2/3/4) have
been shown to be associated with lack of response to anti-
epidermal growth factor receptor (EGFR) therapy [5]. Therefore,
guidelines now recommend that RAS wild-type (WT) tumor sta-
tus should be confirmed before starting this treatment [6].
However, additional biomarkers are still needed as not all RAS
WT patients respond to anti-EGFR therapy. HER2 amplification
has been reported as a mechanism of resistance to anti-EGFR
treatment and therapeutic approaches for patients with HER2-
positive mCRC tumors are in development [7]. BRAF V600E
mutations, harbored by 10% of tumors, confer poor prognosis
in mCRC [8]. However, results from two recent meta-analyses
[9, 10] have generated opposing conclusions suggesting that data
are currently insufficient to definitively exclude efficacy of pani-
tumumab or cetuximab in patients with RAS WT/BRAF V600E-
mutated tumors and that more research is needed.
Right-sided colon tumors have a lower incidence, are more
prevalent in females, more frequently carry BRAF mutations,
have a higher tumor/nodes/metastases stage at presentation, and
are associated with worse prognosis than left-sided colorectal
tumors [11–13]. A possible explanation for these differences is
the different embryological origin of the proximal and distal parts
of the colon and colorectum. Both parts are joined together at the
proximal two-thirds and distal one-third of the transverse colon
and have different blood supplies, innervations and lymphatic
drainages [11]. Moreover, tumor sidedness correlates with differ-
ent biological and molecular characteristics [11, 14].
There have been communications reporting the efficacy of bio-
logical agents in mCRC according to primary tumor sidedness
[14–17]. Notably retrospective analyses of two first-line studies
comparing chemotherapy plus cetuximab against chemotherapy
plus bevacizumab reported better results for cetuximab in pa-
tients with left-sided tumors [15–17]. In contrast, patients with
right-sided tumors generally appeared to benefit more from
chemotherapy plus bevacizumab. No publications to date have
investigated the effect of tumor sidedness on panitumumab effi-
cacy. The aim of these retrospective analyses was to investigate
the possible association between tumor sidedness and panitumu-
mab efficacy in patients with RAS WT mCRC undergoing
first-line treatment in two randomized clinical trials.
Materials and methods
Study design and data sources
These retrospective analyses included data from two published random-
ized controlled first-line mCRC trials. PRIME (NCT00364013) was a
phase 3 study assessing the efficacy of panitumumab plus FOLFOX com-
pared with FOLFOX alone [5, 18]. PEAK (NCT00819780) was a
randomized phase 2 study of panitumumab plus FOLFOX or bevacizu-
mab plus FOLFOX [19, 20].
Assessment of tumor sidedness
Information on tumor sidedness was obtained from the free-text surgery
descriptions included in the case report forms and from the original
pathology reports. Primary tumors located in the cecum to transverse
colon were coded as right-sided. Tumors located from the splenic flexure
to rectum were categorized as left-sided. The assessors of tumor sidedness
were blinded to RAS and BRAF mutation status, treatment allocation and
clinical outcomes.
Study population
The primary analysis was carried out on the RAS WT (KRAS/NRAS exon
2/3/4 WT) population in order to study the effect of tumor sidedness on
clinical outcomes in panitumumab-treated mCRC patients. The prog-
nostic impact of tumor side was also assessed after excluding all BRAF
V600E mutant (MT) patients from the RAS WT cohort (i.e. in the RAS/
BRAF WT population).
Statistical analyses
As these were retrospective analyses, no formal hypothesis testing was
planned. The efficacy endpoints evaluated were response rate (RR), dur-
ation of response (DoR), progression-free survival (PFS) and overall sur-
vival (OS).
DoR was calculated from first confirmed response to first occurrence
of progressive disease (PD) per modified Response Evaluation Criteria In
Solid Tumors (RECIST). PFS was calculated from randomization to PD
per modified RECIST or death (whichever occurred first). Patients not
meeting these criteria at the analysis data cut-off had their DoR or PFS
censored at the last evaluable disease assessment. OS was calculated from
randomization to death. Patients who had not died by the analysis data
cut-off had their time of death censored at the last contact date on which
they were known to be alive.
All data were summarized descriptively. The treatment hazard ratio
(HR) for panitumumab relative to FOLFOX alone or to bevacizumab in
combination with FOLFOX and the associated 95% confidence intervals
(CI) were estimated from a stratified Cox proportional hazard model
(Wald tests to generate P-values). For the RAS WT analysis set, the Cox
model was adjusted for BRAF status, previous adjuvant therapy and base-
line Eastern Cooperative Oncology Group (ECOG) score. HRs below one




Overall, the sidedness of the primary tumor could be determined
unequivocally in 83% (559/675) of patients from the RAS WT
populations of PRIME and PEAK. Most of these patients had
left-sided primary tumors (79% and 75%).
In the overall RAS WT population (n¼ 559), BRAF V600E
mutations were present in 5% and 2% of left-sided mCRC pa-
tients in PRIME and PEAK, while 33% and 28% of patients with
right-sided mCRC were BRAF MT, respectively (Table 1). In
PEAK, there was an imbalance by treatment arm in patients with
right-sided disease with 7% (n¼ 1) versus 41% (n¼ 9) of those
in the bevacizumab versus panitumumab arm, respectively
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having BRAF MT mCRC. Median age was similar between pa-
tients with left- and right-sided mCRC.
Prognostic effect of primary tumor sidedness
RAS WT patients with left-sided tumors had better OS, PFS, RR
and DoR outcomes compared with those with right-sided tumors,
irrespective of treatment received (Table 2; Figure 1). The OS HRs
consistently demonstrated worse prognosis for patients with right-
sided tumors (supplementary Table S1, available at Annals of
Oncology online).
After excluding BRAF MT patients from the RAS WT cohort,
prognosis remained poor in patients with RAS/BRAF WT right-
sided mCRC compared with those with left-sided mCRC for each
treatment arm (Table 3).
Predictive effect on OS and PFS of primary tumor
sidedness in RASWT patients
The effect of primary tumor sidedness on OS and PFS outcomes
in RAS WT patients is shown in Table 2 and Figure 1. In PRIME,
RAS WT patients with left-sided tumors benefited from the add-
ition of panitumumab to FOLFOX, as indicated by longer me-
dian OS (30.3 versus 23.6 months, adjusted HR¼ 0.73,
P¼ 0.0112) and PFS (12.9 versus 9.2 months, adjusted
HR¼ 0.72, P¼ 0.0048), compared with patients treated with
FOLFOX alone. No significant differences in median OS or PFS
were observed in patients with right-sided mCRC (OS: 11.1 ver-
sus 15.4 months, adjusted HR¼ 0.87, P¼ 0.5398; PFS: 7.5 versus
7.0 months, adjusted HR¼ 0.80, P¼ 0.3286).
In PEAK, RAS WT patients with left-sided primary tumors had
numerically better median OS (43.4 versus 32.0 months, adjusted
HR¼ 0.77, P¼ 0.3125) and PFS (14.6 versus 11.5 months, ad-
justed HR¼ 0.68, P¼ 0.0732) in the panitumumab versus beva-
cizumab arm. In patients with right-sided tumors, the adjusted
HR for OS favored panitumumab while the PFS HR favored bev-
acizumab (OS: 17.5 versus 21.0 months, HR¼ 0.67, P¼ 0.3239;
PFS: 8.7 versus 12.6 months, HR¼ 1.04, P¼ 0.9085). Despite the
adjusted HR, the right-sided comparison should be evaluated
with caution, as it was based on very few patients.
Effect of primary tumor sidedness on RR and DoR
in the RASWT population
In the PRIME trial, the RR was higher in the panitumumab arm
versus FOLFOX alone in patients with both left-sided (68% ver-
sus 53%) and right-sided (42% versus 35%) tumors. DoR was
also longer in the panitumumab arm than in the control arm on
both sides (Table 2).
In the PEAK trial, a higher RR was also seen for panitumumab
versus bevacizumab in patients with both left-sided (64% versus
57%) and right-sided (64% versus 50%) tumors. Longer median
DoR was seen for panitumumab plus FOLFOX versus bevacizu-
mab plus FOLFOX in patients with left-sided tumors (16.1 versus
9.5 months), while no difference was seen in patients with right-
sided disease (8.7 versus 9.2 months).
Predictive effect on OS and PFS of primary tumor
sidedness in RAS/BRAFWT patients
In PRIME, RAS/BRAF WT patients with left-sided tumors bene-
fited from the addition of panitumumab to FOLFOX, as indi-
cated by longer median OS (32.5 versus 23.6 months, adjusted
HR¼ 0.68, P¼ 0.0027) and PFS (12.9 versus 9.3 months,
Table 1. Baseline demographics and disease characteristics of the RAS WT population
Baseline characteristic PRIME PEAK
Pmab arm Comparator arm Pmab arm Comparator arm
Left Right Left Right Left Right Left Right
Patient number 169 39 159 49 53 22 54 14
Baseline ECOG, n (%) Missing – – 1 (0.6) – – – – –
0 106 (62.7) 22 (56.4) 88 (55.3) 27 (55.1) 37 (69.8) 10 (45.5) 35 (64.8) 9 (64.3)
1 56 (33.1) 15 (38.5) 61 (38.4) 19 (38.8) 16 (30.2) 12 (54.5) 19 (35.2) 5 (35.7)
2 7 (4.1) 2 (5.1) 9 (5.7) 3 (6.1) – – – –
Prior adjuvant chemotherapy, n (%) No 140 (82.8) 29 (74.4) 133 (83.6) 39 (79.6) 45 (84.9) 18 (81.8) 41 (75.9) 10 (71.4)
Yes 29 (17.2) 10 (25.6) 26 (16.4) 10 (20.4) 8 (15.1) 4 (18.2) 13 (24.1) 4 (28.6)
Sex, n (%) Female 49 (29.0) 18 (46.2) 56 (35.2) 24 (49.0) 19 (35.8) 7 (31.8) 16 (29.6) 4 (28.6)
Male 120 (71.0) 21 (53.8) 103 (64.8) 25 (51.0) 34 (64.2) 15 (68.2) 38 (70.4) 10 (71.4)
BRAF status, n (%) Test failure 6 (3.6) 0 (0.0) 3 (1.9) 1 (2.0) – – – –
Mutant 7 (4.1) 13 (33.3) 8 (5.0) 16 (32.7) 1 (1.9) 9 (40.9) 1 (1.9) 1 (7.1)
Wild-type 156 (92.3) 26 (66.7) 148 (93.1) 32 (65.3) 52 (98.1) 13 (59.1) 53 (98.1) 13 (92.9)
Sites of metastasis, n (%) Liverþother 119 (70.4) 21 (53.8) 108 (67.9) 35 (71.4) 21 (39.6) 13 (59.1) 21 (38.9) 9 (64.3)
Liver only 33 (19.5) 6 (15.4) 31 (19.5) 5 (10.2) 18 (34.0) 4 (18.2) 15 (27.8) 4 (28.6)
Other only 17 (10.1) 12 (30.8) 20 (12.6) 9 (18.4) 14 (26.4) 5 (22.7) 18 (33.3) 1 (7.1)
Age, years (range) Median 61 (27, 81) 62 (42, 80) 62 (27, 82) 61 (24, 78) 60 (23, 77) 64 (43, 82) 60 (39, 82) 66 (50, 78)
ECOG, Eastern Cooperative Oncology Group; n, number; Pmab, panitumumab.
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adjusted HR¼ 0.69, P¼ 0.0028), compared with FOLFOX alone
(Table 3). No significant differences in median OS (22.5 versus
21.5 months, adjusted HR¼ 0.97, P¼ 0.9295) or PFS (8.9 versus
7.3 months, adjusted HR¼ 0.75, P¼ 0.3260) were observed in
patients with right-sided mCRC.
In PEAK, RAS/BRAF WT patients with left-sided tumors had
numerically better median OS (43.4 versus 32.0 months, ad-
justed HR¼ 0.76, P¼ 0.2945) and PFS (14.6 versus
11.5 months, adjusted HR¼ 0.65, P¼ 0.0514) in the panitumu-
mab versus bevacizumab arm. In patients with right-sided
tumors, median OS was 22.5 versus 23.3 months (adjusted
HR¼ 0.64, P¼ 0.3326) and PFS was 10.3 versus 12.6 months
(adjusted HR¼ 0.90, P¼ 0.8092) in the panitumumab versus
bevacizumab arm, respectively.
Discussion
This is the first publication reporting the effect of primary tumor
sidedness on clinical outcomes during panitumumab treatment.
Data from two randomized first-line panitumumab mCRC trials
were retrospectively analyzed according to tumor sidedness.
Table 2. Efﬁcacy outcomes in the RAS WT population
Study Treatment n patients OS (m) PFS (m) RR (%) DoR (m)
Left Right Left Right Left Right Left Right Left Right
PRIME Pmabþ 169/168a 39/ 30.3 11.1 12.9 7.5 67.9 42.1 11.8 9.7
FOLFOX 38a (25.8, 36.1) (8.1, 25.2) (10.0, 14.6) (5.5, 10.4) (9.6, 14.8) (3.9, 13.3)
FOLFOX 159/156a 49/46a 23.6 15.4 9.2 7.0 52.6 34.8 9.3 7.6
(18.2, 26.9) (9.1, 21.7) (7.6, 10.7) (5.4, 8.0) (7.7, 11.0) (4.2, 9.4)
Adjusted HRb 0.73 0.87 0.72 0.80 1.91c 1.36c
(0.57, 0.93) (0.55, 1.37) (0.57, 0.90) (0.51, 1.26) (1.18, 3.07) (0.51, 3.62)
P-value 0.0112 0.5398 0.0048 0.3286 – –
PEAK Pmabþ 53/ 22/ 43.4 17.5 14.6 8.7 64.2 63.6 16.1 8.7
FOLFOX 53a 22a (31.6, 63.0) (9.1, 30.7) (11.6, 17.7) (5.7, 10.9) (11.1, 20.9) (3.7, 14.2)
Bmabþ 54/ 14/ 32.0 21.0 11.5 12.6 57.4 50.0 9.5 9.2
FOLFOX 54a 14a (26.0, 47.4) (6.0, 29.0) (9.3, 13.0) (1.8, 16.6) (7.9, 13.8) (5.9, 16.6)
Adjusted HRb 0.77 0.67 0.68 1.04 1.33c 1.75c
(0.46, 1.28) (0.30, 1.50) (0.45, 1.04) (0.50, 2.18) (0.57, 3.11) (0.36, 8.39)
P-value 0.3125 0.3239 0.0732 0.9085 – –
aNumber of patients assessable for response.
bAdjusted treatment HR calculated from model with factors for BRAF status, prior adjuvant therapy and baseline ECOG. HR below 1 favors pmab arm
(PRIME, PEAK).
cOdds ratio for treatment difference in RR presented. An odds ratio >1 favors the pmab arm (PRIME, PEAK).
Bmab, bevacizumab; DoR (m), duration of response in months; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; n, number; OS (m), overall
survival in months; PFS (m), progression-free survival in months; Pmab, panitumumab; RR, response rate.
Table 3. Efﬁcacy outcomes in the RAS/BRAF WT population
Study Treatment n Patients OS (m) PFS (m)
Left Right Left Right Left Right
PRIME PmabþFOLFOX 156 26 32.5 (27.5, 37.6) 22.5 (8.1, 30.8) 12.9 (10.0, 14.9) 8.9 (5.5, 11.3)
FOLFOX 148 32 23.6 (18.2, 27.7) 21.5 (10.8, 26.0) 9.3 (7.7, 10.8) 7.3 (4.2, 11.1)
Adjusted HRa 0.68 (0.52, 0.87) 0.97 (0.55, 1.74) 0.69 (0.54, 0.88) 0.75 (0.42, 1.33)
P-value 0.0027 0.9295 0.0028 0.3260
PEAK PmabþFOLFOX 52 13 43.4 (34.2, 63.0) 22.5 (8.4, 36.9) 14.6 (11.6, 18.1) 10.3 (6.1, 11.6)
BmabþFOLFOX 53 13 32.0 (26.9, 48.5) 23.3 (6.0, 29.0) 11.5 (9.3, 13.0) 12.6 (1.8, 18.4)
Adjusted HRb 0.76 (0.45, 1.27) 0.64 (0.26, 1.58) 0.65 (0.43, 1.00) 0.90 (0.39, 2.07)
P-value 0.2945 0.3326 0.0514 0.8092
aAdjusted treatment HR calculated from model with factors for region and baseline ECOG. HR below 1 favors the pmab arm (PRIME).
bAdjusted treatment HR calculated from model with factors for prior adjuvant oxaliplatin therapy. HR below 1 favors the pmab arm (PEAK).
Bmab, bevacizumab; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; n, number; OS (m), overall survival in months; PFS (m), progression-
free survival in months; Pmab, panitumumab.
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These analyses confirmed the prognostic effect of tumor sidedness
in patients with RAS WT and RAS/BRAF WT mCRC, in line with
data previously reported in the literature [12, 15, 17, 21, 22].
Regardless of first-line treatment received, RAS WT patients with
right-sided tumors had worse prognosis than those with left-sided
tumors. In a second analysis, we excluded all BRAF V600E MT pa-
tients to evaluate whether the prognostic effect still stood in a first-line
RAS/BRAF WT population. This is important as BRAF mutations
negatively impact survival and are more frequently present in right-
than left-sided tumors [14, 23, 24]. In our population<5% of patients
with left-sided mCRC had BRAF mutations, while these mutations
were present in 28%–33% of right-sided mCRC patients. Considering
the high proportion of BRAF mutations in patients with right-sided
tumors, median OS is clearly better once patients with these muta-
tions are removed from the analysis, supporting the prognostic rele-
vance of BRAF in this subgroup of patients with right-sided mCRC.
However, in the RAS/BRAF WT population, right-sided primary
tumors were still linked to poorer prognosis compared with left-sided
primary tumors, corroborating previously reported work [21, 23].
Regarding the predictive effect of tumor sidedness on efficacy of
anti-EGFR therapy, most recent data comes from first-line studies
comparing chemotherapy with either bevacizumab or cetuximab.
In the re-analysis of CALGB/SWOG 80405 according to tumor
sidedness, OS and PFS were prolonged in the cetuximab arm in
RAS WT patients with left-sided tumors [16, 17]. Conversely, pa-
tients with right-sided tumors had better outcomes in the bevaci-
zumab arm; however, no BRAF data from CALGB/SWOG 80405
have been presented and, as we have seen in our own results, im-
balances in the proportion of patients with this biomarker can im-
pact median OS. At the time of writing, results from the CALGB
trial have not yet been fully published. Therefore, caution should
be used when reviewing these data as significant open questions re-
main, such as treatment exposure and use of post-PD therapy in
each arm. Considering the other phase 3 trial comparing cetuxi-
mab plus chemotherapy with bevacizumab plus chemotherapy in
first-line mCRC (FIRE-3), a retrospective analysis showed similar
results, both in terms of the prognostic and predictive impact (left-
sided tumors had better prognosis compared with right-sided
tumors regardless of treatment; cetuximab was better than bevaci-
zumab in left-sided disease, bevacizumab better in right-sided)
[15, 25]. Another recent communication revealed that the primary
tumor side’s association with OS and PFS during cetuximab treat-
ment did not remain significant after multivariate analysis adjust-
ing for an extensive biomarker panel, suggesting that mutations in
BRAF and NRAS, tumor methylation and (perhaps) gene expres-
sion patterns may account for the observed effect [26].
Here we report that patients with left-sided primary tumors
benefit from the addition of panitumumab to chemotherapy in
Median OS (95% CI), months
Pmab + FOLFOX
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Median PFS (95% CI), months
Pmab + FOLFOX 12.9 (10.0, 14.6) 7.5 (5.5, 10.4)
FOLFOX 9.2 (7.6, 10.7) 7.0 (5.4, 8.0)
HR 0.72 (0.57, 0.90) 0.80 (0.51, 1.26)
1: Pmab + FOLFOX left side
2: FOLFOX left side
3: Pmab + FOLFOX right side
4: FOLFOX right side
1: Pmab + FOLFOX left side
2: Bmab + FOLFOX left side
3: Pmab + FOLFOX right side
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Pmab + FOLFOX
Censor indicated by vertical bar I
43.4 (31.6, 63.0) 17.5 (9.1, 30.7)
Bmab + FOLFOX 32.0 (26.0, 47.4) 21.0 (6.0, 29.0)
HR 0.77 (0.46, 1.28) 0.67 (0.30, 1.50)
Left Right
Median PFS (95% CI), months
Pmab + FOLFOX 14.6 (11.6, 17.7) 8.7 (5.7, 10.9)
Bmab + FOLFOX 11.5 (9.3, 13.0) 12.6 (1.8, 16.6)
HR 0.68 (0.45, 1.04) 1.04 (0.50, 2.18)
Left Right
Figure 1. Overall survival and progression-free survival in the RAS WT populations for (A) PRIME and (B) PEAK. Bmab, bevacizumab; CI, conﬁ-
dence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; Pmab, panitumumab.
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the first-line PRIME and PEAK trials. RAS WT patients with left-
sided tumors in the panitumumab arm had better OS (6.7 and
11.4 months difference respectively), PFS (3.7 and 3.1 months
difference, respectively), RRs (15.3 and 6.8 absolute difference in
percentage points) and DoR (2.5 and 6.6 months difference) than
the chemotherapy arm, with or without bevacizumab. These
findings are in line with results from other recent studies [15, 16].
In RAS WT patients with right-sided tumors, numerically
higher RRs were observed in patients receiving panitumumab
compared with comparator treatments, again, consistent with
other communicated findings [15, 16]. For OS and PFS in the
RAS WT right-sided population, most medians were better in the
control arm. In relation to imbalances in baseline characteristics,
adjusted OS HRs (calculated from a model including BRAF sta-
tus, prior adjuvant chemotherapy and baseline ECOG) were in
favor of the panitumumab arms, although P-values were not sig-
nificant. However, results for patients with right-sided primary
tumors have to be taken with caution due to the small sample
sizes and small absolute differences between arms.
A limitation of our study is the retrospective exploratory na-
ture of these analyses. Therefore, our population is not controlled
for subgroup imbalances. This was partially tackled by adjusting
the HR calculations. In addition, we have no data on other bio-
markers beyond RAS and BRAF, such as microsatellite instability
or methylation, which might also affect clinical outcomes. A
strength of this study was the high tumor sidedness ascertain-
ment, which was blinded to allocated treatment and clinical out-
come. In addition, there was a high RAS/BRAF ascertainment
rate and the analyses were carried out on clean data from two
published randomized clinical trials, one of which was conducted
with registrational intent.
In summary, first-line panitumumab plus chemotherapy pro-
vided better OS, PFS and RRs compared with first-line chemo-
therapy with or without bevacizumab in RAS WT patients with
left-sided primary tumors in these two studies. These results con-
solidate evidence from other trials suggesting anti-EGFR therapy
plus chemotherapy as being the preferred first-line treatment op-
tion for left-sided mCRC. In patients with right-sided disease, the
data are inconclusive and based on the present analyses it is not
possible to draw definitive conclusions on optimum treatment.
Further research on biomarkers is warranted to identify a poten-
tial subgroup of patients with right-sided mCRC who might
benefit from panitumumab.
It is clear that proximal and distal CRC should be considered as
different clinical entities and tumor sidedness should be considered
when making treatment decisions. It should also be included as a
stratification factor in future randomized clinical trials, including
those assessing impact of treatment sequence, which may also in-
fluence long-term outcome. Tumor sidedness is a simple variable,
which cannot replace molecular characterization of the tumor but
may in part stand as a surrogate for complex and still partially
understood tumor biology and thus aid clinical decision-making.
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